STUDY OF LIPID PROFILE AND ATHEROGENIC INDEX IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

DURAIN FATIMA; SURYA TIWARI; PRAVIN S GOWARDIPE; SADAWARTE SK

doi:10.22159/ajpcr.2022.v15i12.46238

Authors

DURAIN FATIMA Department of Physiology, People’s College of Medical Sciences and Research Centre, Bhopal, Madhya Pradesh, India. https://orcid.org/0000-0003-0506-7514
SURYA TIWARI Department of Biochemistry, Chirayu Medical College and Hospital, Bhopal, Madhya Pradesh, India.
PRAVIN S GOWARDIPE Department of Physiology, Chirayu Medical College and Hospital, Bhopal, Madhya Pradesh, India. https://orcid.org/0000-0002-0299-3224
SADAWARTE SK Department of Physiology, People’s College of Medical Sciences and Research Centre, Bhopal, Madhya Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i12.46238

Keywords:

Chronic obstructive pulmonary disease, Lipid, Atherogenic index, Atherosclerosis

Abstract

Objectives: The present study’s design investigated the lipid parameters level and atherogenic index in atherosclerosis and cardiovascular disease risk development in chronic obstructive pulmonary disease patients.

Methods: The study consists of 108 clinically diagnosed and confirmed spirometry-stable chronic obstructive pulmonary disease (COPD) patients (Mild, Moderate, and Severe), and the controls were 36 healthy individuals of the same age and sex. Blood samples were collected and the lipid profile was done. The atherogenic index of all COPD patients was calculated using the values of lipid parameters.

Results: The observation revealed that as compared to the control group, total cholesterol, triglycerides, low-density lipoproteins (LDL), and very LDLs were significantly (p<0.001) raised in all the COPD sub-groups, and high-density lipoproteins levels showed significantly (p<0.001) decreasing levels in all COPD groups as compared to controls. The COPD sub-group has a higher atherogenic risk (p<0.001) than controls.

Conclusion: In COPD patients with dyslipidemia, there is an increased atherogenic risk, which predicts future cardiovascular risk.

Downloads

Download data is not yet available.

Author Biographies

DURAIN FATIMA, Department of Physiology, People’s College of Medical Sciences and Research Centre, Bhopal, Madhya Pradesh, India.

Assistant Professor, Department of Physiology, Chirayu Medical College & Hospital Bhopal, Madhya Pradesh, India

SURYA TIWARI, Department of Biochemistry, Chirayu Medical College and Hospital, Bhopal, Madhya Pradesh, India.

Assistant Professor, Department of Biochemistry, Chirayu Medical College & Hospital Bhopal, Madhya Pradesh, India

PRAVIN S GOWARDIPE, Department of Physiology, Chirayu Medical College and Hospital, Bhopal, Madhya Pradesh, India.

Assistant Professor, Department of Physiology, Chirayu Medical College & Hospital Bhopal, Madhya Pradesh, India

References

Jindal SK, Gupta D, Aggarwal AN. Guidelines for the management of chronic obstructive pulmonary disease in India: A guide for physician (2003). Indian J Chest Dis Allied Sci 2004;46:137-93.

Van Iwaarden F, Welmers B, Verhoef J, Haagsman HP, Van Golde LM. Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 1990;12:91-8.

Mannino DM, Buist AS. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet 2007;370:765-73.

Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012;379:1341-51.

Maclay JD, MacNee W. Cardiovascular disease in COPD: Mechanisms. Chest 2013;143:798-807.

Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.

Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al. Assessment of coronary artery disease by cardiac computed tomography: A scientific statement from the American Heart association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and a committee on cardiac imaging, council on clinical cardiology. Circulation 2006;114:1761-91.

Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291:210-5.

Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: A systematic review and meta-analysis. Arch Intern Med 2004;164:1285-92.

Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, et al. Atherogenic index of plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran 2015;29:240.

Shen S, Lu Y, Qi H, Li F, Shen Z, Wu L, et al. Association between ideal cardiovascular health and the atherogenic index of plasma. Medicine (Baltimore) 2016;95:e3866.

Dobiášová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001;34:583-8.

European Respiratory Society. ATS COPD Guidelines European Respiratory Society. Switzerland: European Respiratory Society; 2005.

Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2018 Report.

Allian CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of Total serum cholesterol 1974;20:470-5.

Werner M, Gabrielson DG, Eastman J. Ultramicro determination of serum triglyceride by bioluminescent assay. Clin Chem 1981;27:268-71.

Burstein M, Scholnick HR, Morfin R. Rapid method for isolation of lipoproteins from human serum by precipitation with poluanions. J Lipid Res 1970;11:583-95.

Knopfholz J, Disserol CC, Pierin AJ, Schirr FL, Streisky L, Takito LL, et al Validation of the friedewald formula in patients with metabolic syndrome. Cholesterol 2014;2014:261878.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

Frohlich J., Dobiášová M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003;49:1873-80.

Dobiasova M. Atherogenic index of plasma [log (triglycerides/ HDL-cholesterol): theoretical and practical implications. Clin Chem 2004;50:1113-5.

Fabbri LM, Luppi F, Beghe´ B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-12.

Roversi S, Roversi P, Spadafora G, Rossi R, Fabbri LM. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest 2014;44:93-102.

Corbi G, Bianco A, Turchiarelli V, Cellurale M, Fatica F, Daniele A, et al. Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: Focus on sirtuins. Int J Mol Sci 2013;14:12696-713.

Bellocchia M, Masoero M, Ciuffreda A, Croce S, Vaudano A, Torchio R, et al. Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease. Multidiscip Respir Med 2013;8:58.

Alvarado A, Arce I. Metabolic functions of the Lung, disorders and associated pathologies. J Clin Med Res 2016;8:689-700.

Lamonaca P, Prinzi G, Kisialiou A, Cardaci V, Fini M, Russo P. Metabolic disorder in chronic obstructive pulmonary disease (COPD) patients: Towards a personalized approach using marine drug derivatives. Mar Drugs 2017;15:81.

Kilk K, Aug A, Ottas A, Soomets U, Altraja S, Altraja A. Phenotyping of chronic obstructive pulmonary disease based on the integration of metabolomes and clinical characteristics. Int J Mol Sci 2018;19:666.

Yedgar S, Krimsky M, Cohen Y, Flower RJ. Treatment of inflammatory diseases by selective eicosanoid inhibition: A double-edged sword? Trends Pharmacol Sci 2007;28:459-64.

Markelic I, Hlapcic I, Rogic D, Rako I, Samarzija M, Popovic-Grle S, et al. Lipid profile and atherogenic indices in patients with stable chronic obstructive pulmonary disease: Nutr Metab Cardiovasc Dis 2021;31:153e161.

Kumar JR, Mahajan S, Mehta D, Ambad RS, Koundal P. Lipid profile in patients with COPD: A cross-sectional study. Int J Med Biomed Stud 2020;4:121-6.

Andréa S, Conde B, Fragosoc E, Boléo-Tomé JP, Areias V, Cardosog J. COPD and cardiovascular disease. Pulmonology 2019;25:168-76.

Eriksson B, Lindberg A, Müllerova H, Rönmark E, Lundbäck B. Association of heart diseases with COPD and restrictive lung function- -results from a population survey. Respir Med 2013;107:98-106.

Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kir VA. Relationship between lung function impairment and incidence or recurrence of a cardiovascular event in a middle-aged cohort. Thorax 2008;63:599-605.

Sharma H, Kapur P, Jalali KR, Dubey K. Atherosclerosis risk assessment in patients with chronic obstructive pulmonary disease: A case-control study. Ther Clin Risk Manag 2019;15:1061-71.